Keyphrases
Clinical Trials
100%
Triple-negative Breast Cancer
100%
Pathological Response
100%
Pathological Complete Response
100%
Carboplatin
100%
Docetaxel
100%
Treatment-seeking Sample
25%
Whole Exome Sequencing
16%
Complete Response Rate
16%
Neoadjuvant
16%
Immune Profiling
16%
Residual Cancer Burden
16%
Immune Gene Signature
16%
CD-8
8%
Tumor
8%
Tumor Samples
8%
Treg
8%
Mutated Genes
8%
Trial Registration
8%
Neoadjuvant Trials
8%
Stage II-III
8%
Molecular Characterization
8%
Programmed Death-ligand 1 (PD-L1)
8%
Cytotoxic Cells
8%
Cytotoxicity
8%
Neoadjuvant Chemotherapy
8%
Risk of Death
8%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
8%
Inflammatory Chemokines
8%
Significant Trend
8%
Tumor Protein p53 (TP53)
8%
Interferon-γ Signalling
8%
Molecular Profile
8%
Online Treatment
8%
Indoleamine 2,3-dioxygenase 1 (IDO1)
8%
Molecular Alterations
8%
Tumor Inflammation
8%
High-risk of Recurrence
8%
L1 Cell Adhesion Molecule (L1CAM)
8%
6-cycles
8%
PD-L2
8%
Mutation Burden
8%
COL4A5 mutation
8%
COL22A1
8%
Immunoproteasome
8%
Clinical Trial Information
8%
CACNA1S
8%
Medicine and Dentistry
Clinical Trial
100%
Carboplatin
100%
Triple Negative Breast Cancer
100%
Docetaxel
100%
Immunity
80%
Malignant Neoplasm
40%
Neoplasm
40%
Exome Sequencing
40%
CD8 Antigen
20%
Clinical Stage
20%
Cancer Treatment
20%
Recurrent Disease
20%
Cytotoxic T-Cell
20%
Epidermal Growth Factor Receptor
20%
Neoadjuvant Chemotherapy
20%
Programmed Death-Ligand 1
20%
Cytotoxicity
20%
Chemokine
20%
Gamma Interferon
20%
Pharmacology, Toxicology and Pharmaceutical Science
Triple Negative Breast Cancer
100%
Clinical Trial
100%
Carboplatin
100%
Docetaxel
100%
Neoplasm
60%
Malignant Neoplasm
40%
Chemotherapy
20%
Inflammation
20%
Epidermal Growth Factor Receptor
20%
CD8 Antigen
20%
Recurrent Disease
20%
Gamma Interferon
20%
Chemokine
20%
Cytotoxicity
20%
Cytotoxic T Lymphocyte Antigen 4
20%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Immunity
100%
Exome Sequencing
50%
Gene Signature
50%
Epidermal Growth Factor Receptor
25%
Mutated Genes
25%
CD8
25%
Cytotoxicity
25%
Interferon Gamma
25%
Chemokine
25%
Regulatory T Cell
25%
PD-L1
25%
COL4A5
25%